BeiGene, Ltd. - American Depositary Shares (NQ:BGNE)

184.71 UNCHANGED

Last Price Updated: 4:00 PM EST, Dec 31, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about BeiGene, Ltd. - American Depositary Shares

< Previous 1 2

...

10 11 12 13 14 15 16 17 Next >

BeiGene Announces European Medicines Agency Acceptance of Marketing Authorization Applications for Tislelizumab for the Treatment of Patients with ESCC and NSCLC

April 06, 2022

From BeiGene

Via Business Wire

The Gift Chinese Regulators Just Gave Tech Stocks Like Alibaba And BeiGene ↗

April 04, 2022

Auditing issues persist for some 270 companies trading in the U.S. But they could ease.

Via Investor's Business Daily

Most Chinese Biotech Stocks Can Continue US Listing After New Audit Framework ↗

April 01, 2022

Via Benzinga

Which Chinese Stocks Will Be Delisted? 8 in U.S. Crosshairs ↗

March 28, 2022

As these Chinese stocks face delisting, some may provide a contrarian play on improving relations between the U.S. and China.

Via InvestorPlace

BeiGene: Q4 Earnings Insights ↗

February 25, 2022

BeiGene (NASDAQ:BGNE) reported its Q4 earnings results on Friday, February 25, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings...

Via Benzinga

CStone's Commercialization Capacity Put to Test With Latest Drug Approval ↗

February 14, 2022

Key takeaways:

Via Benzinga

Which Chinese Stocks Could Get Delisted? 6 Companies to Watch. ↗

March 25, 2022

Today, news that Weibo has been added to the SEC's list of at-risk companies for delisting has investors selling Chinese stocks in a big way.

Via InvestorPlace

Analyst Ratings For BeiGene ↗

March 17, 2022

Over the past 3 months, 4 analysts have published their opinion on BeiGene (NASDAQ:BGNE) stock. These analysts are typically employed by large Wall Street banks and tasked with...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 17, 2022 ↗

March 17, 2022

Upgrades Loop Capital upgraded the previous rating for Aspen Technology Inc (NASDAQ:AZPN) from Hold to Buy. In the second quarter, Aspen Technology showed an EPS of $1.20,...

Via Benzinga

10 Biggest Price Target Changes For Thursday ↗

March 17, 2022

Keybanc cut the price target on Darden Restaurants, Inc. (NYSE: DRI) from $170 to $160. Darden shares rose 0.1% to $129.69 in pre-market trading. RBC Capital lowered Union...

Via Benzinga

BeiGene and Medison Announce Approval and National Reimbursement in Israel for BRUKINSA® (zanubrutinib) for the Treatment of Waldenström's Macroglobulinemia

March 15, 2022

From BeiGene

Via Business Wire

The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings ↗

March 13, 2022

Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments...

Via Benzinga

Chinese Stock Delisting News: Why Are BABA, DIDI, IQ, YUMC, ACMR, BGNE and ZLAB Down Today? ↗

March 11, 2022

Chinese stock delisting news today has several big names in the country seeing their shares slip on fears they could be next.

Via InvestorPlace

What's Going On With Zai Lab, Hutchmed, BeiGene Shares Today ↗

March 11, 2022

Three of the most major drugmakers with roots in China, Zai Lab Ltd (NASDAQ: ZLAB), BeiGene Ltd (NASDAQ: BGNE), and Hutchmed China Ltd (NASDAQ: HCM...

Via Benzinga

The Daily Biotech Pulse: Valneva Gains On COVID Shot Regulatory Update, Lucira Health And Clearside Jump On Earnings, BeiGene Drug Snags Approval In China ↗

March 11, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Valneva Says Confident Of Conditional Approval For COVID Vaccine Candidate In...

Via Benzinga

Chinese Stocks Are Falling: What's Going On? ↗

March 10, 2022

Shares of multiple Chinese companies are trading lower Thursday following reports the U.S. Securities and Exchange Commision has identified multiple US-listed ADRs as...

Via Benzinga

Why BeiGene — And 2 Other China-Based Biotechs — Are In Trouble ↗

March 10, 2022

The SEC is calling out a several stocks for non-compliance. Could they face delisting?

Via Investor's Business Daily

Zai Lab Revenue Triples, As It Struggles To Break Cycle Of Mounting Losses ↗

March 08, 2022

Key takeaways: Zai Lab reported its revenue grew 194% last year, but its loss also increased by 162% as it spent heavily on R&D and marketing The company hopes heavy R&D...

Via Benzinga

The Daily Biotech Pulse: NuCana Shelves Biliary Tract Cancer Study, Tricida Data Readout Pushed Back Due to Ukrainian Crisis, Synlogic Names New CFO ↗

March 03, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus NuCana Discontinues Biliary Tract Cancer Study Following Futility Analysis...

Via Benzinga

BeiGene Reports Fourth Quarter and Full Year 2021 Financial Results

February 25, 2022

From BeiGene, Ltd.

Via Business Wire

BeiGene's Brukinsa Applications Under FDA, European Review For Leukemia ↗

February 22, 2022

The European Medicines Agency (EMA) has accepted for review two new indication applications for BeiGene Ltd's (NASDAQ: BGNE) Brukinsa (zanubrutinib) for...

Via Benzinga

BeiGene Announces U.S. FDA Acceptance of Supplemental New Drug Application for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia

February 22, 2022

From BeiGene

Via Business Wire

BeiGene Announces European Medicines Agency Acceptance of Applications for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia and Marginal Zone Lymphoma

February 22, 2022

From BeiGene

Via Business Wire

BeiGene Announces Approval for BRUKINSA (zanubrutinib) by Swissmedic for Treatment of Adult Patients with Waldenström’s Macroglobulinemia

February 17, 2022

From BeiGene

Via Business Wire

BeiGene to Present at the Guggenheim Healthcare Talks - 2022 Oncology Conference

February 08, 2022

From BeiGene, Ltd.

Via Business Wire

Drs. Margaret Dugan and Alessandro Riva Appointed to BeiGene Board of Directors

February 01, 2022

From BeiGene

Via Business Wire

The Daily Biotech Pulse: Biogen Liquidates Out Of Biosimilar JV, Provention Bio Plots Diabetes Drug Resubmission, Merck Finds COVID Pill Effective Against Omicron ↗

January 28, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

BeiGene Announces Acceptance of Supplemental New Drug Application in China for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia with Breakthrough Therapy Designation

January 28, 2022

From BeiGene

Via Business Wire

Immix Biopharma's IMX-110 / Anti-PD-1 Combo Therapy Shows Extended Median Survival In Animal Studies ↗

January 25, 2022

Immix Biopharma Inc's (NASDAQ: IMMX) IMX-110 + anti-PD-1 produced 63-day median survival in a genetic pancreatic cancer mouse model, in which mice develop their own...

Via Benzinga

New Energy Lands as Hottest Category Among Chinese Concept Stocks in 2021 – Bamboo Works Special Report ↗

January 26, 2022

Investors kept a close look at China’s solar and wind power stocks last year, but were least interested in the hobbled education sector By Bamboo Works team Chinese concept...

Via Benzinga

< Previous 1 2

...

10 11 12 13 14 15 16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.